MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D

MD Anderson and industry partners to conduct T cell studies on the International Space Station

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.

August 02, 2024

Vol.50 No.31

In Brief

MD Anderson, Rice form Cancer Bioengineering Collaborative

The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Upregulating TERT gene expression reverses multiple hallmarks of aging

Researchers at MD Anderson Cancer Center have demonstrated that therapeutically restoring ‘youthful’ levels of a specific subunit of the telomerase enzyme can significantly reduce the signs and symptoms of aging in preclinical models.

June 28, 2024

Vol.50 No.26

In Brief

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

The Institute for Data Science in Oncology at MD Anderson Cancer Center has established an internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.

June 21, 2024

Vol.50 No.25

Clinical Roundup

MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders

The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.

June 14, 2024

Vol.50 No.24

MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D

YOU MAY BE INTERESTED IN

MD Anderson and industry partners to conduct T cell studies on the International Space Station

MD Anderson, Rice form Cancer Bioengineering Collaborative

Upregulating TERT gene expression reverses multiple hallmarks of aging

MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders

Renew today!

Subscriber content

Login